VP4 Mutation Boosts Replication of Recombinant Human/Simian Rotavirus in Cell Culture
Viruses · 2024
DOI: 10.3390/v16040565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Roman Valusenko-Mehrkens und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Safety, German Federal Institute for Risk Assessment, 10589 Berlin, Germany. Hauptthemen laut MEDLINE: Rotavirus, Virus Replication, Capsid Proteins, Reassortant Viruses. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, German Research Foundation (DFG).
Abstract (Originalsprache)
Rotavirus A (RVA) is the leading cause of diarrhea requiring hospitalization in children and causes over 100,000 annual deaths in Sub-Saharan Africa. In order to generate next-generation vaccines against African RVA genotypes, a reverse genetics system based on a simian rotavirus strain was utilized here to exchange the antigenic capsid proteins VP4, VP7 and VP6 with those of African human rotavirus field strains. One VP4/VP7/VP6 (genotypes G9-P[6]-I2) triple-reassortant was successfully rescued, but it replicated poorly in the first cell culture passages. However, the viral titer was enhanced upon further passaging. Whole genome sequencing of the passaged virus revealed a single point mutation (A797G), resulting in an amino acid exchange (E263G) in VP4. After introducing this mutation into the VP4-encoding plasmid, a VP4 mono-reassortant as well as the VP4/VP7/VP6 triple-reassortant replicated to high titers already in the first cell culture passage. However, the introduction of the same mutation into the VP4 of other human RVA strains did not improve the rescue of those reassortants, indicating strain specificity. The results show that specific point mutations in VP4 can substantially improve the rescue and replication of recombinant RVA reassortants in cell culture, which may be useful for the development of novel vaccine strains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Safety, German Federal Institute for Risk Assessment, 10589 Berlin, Germany.
ORCID-Profile: Katja Schilling-Loeffler, Reimar Johne
Förderung
- Deutsche Forschungsgemeinschaft
- German Research Foundation (DFG)
Zitieren
APA
Valusenko-Mehrkens, R., Schilling-Loeffler, K., Johne, R., & Falkenhagen, A. (2024). VP4 Mutation Boosts Replication of Recombinant Human/Simian Rotavirus in Cell Culture. Viruses. https://doi.org/10.3390/v16040565
Vancouver
Valusenko-Mehrkens R, Schilling-Loeffler K, Johne R, Falkenhagen A. VP4 Mutation Boosts Replication of Recombinant Human/Simian Rotavirus in Cell Culture. Viruses. 2024. doi:10.3390/v16040565
BibTeX
@article{ValusenkoMehrkens2024,
author = {Valusenko-Mehrkens, Roman and Schilling-Loeffler, Katja and Johne, Reimar and Falkenhagen, Alexander},
title = {VP4 Mutation Boosts Replication of Recombinant Human/Simian Rotavirus in Cell Culture},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16040565}
}
EUVIMED